Menu

Trial Launched to Treat Parkinson’s with Reprogrammed Stem Cells

Surgeons will inject approximately 5 million dopamine-producing progenitor cells into patients’ brains.

Jul 31, 2018
Diana Kwon

On Monday (July 30), researchers at Kyoto University in Japan announced that they were launching a clinical trial to treat Parkinson’s disease using reprogrammed adult stem cells. 

“This will be the world’s first clinical trial using [induced pluripotent stem] cells on Parkinson’s disease,” Jun Takahashi, a neurosurgeon at Kyoto University’s Centre for iPS Cell Research and Application, told reporters (via Reuters). 

Takahashi and his colleagues will inject dopamine-producing neural progenitor cells—derived from induced pluripotent stem cells (iPSCs) from healthy adult donors—into Parkinson’s patients’ brains. Approximately 5 million cells will be injected into the patients’ striatum (in red above), the primary brain region implicated in the disease. 

The team plans to recruit seven participants and to observe each patient for two years after the injection. 

Last year, Takahashi and his colleagues reported that the injected cells could survive in monkey brains for up to two years, and that the treatment improved symptoms in a primate model of Parkinson’s disease.

See “Parkinson’s Disease Cell Therapy Relieves Symptoms in Monkeys

According to Science, this is the third iPSC clinical trial approved in Japan. The other two are aimed at treating age-related macular degeneration and heart disease.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.